TSPO PET using ¹⁸F-GE-180: a new perspective in neurooncology?

Karl-Josef Langen^{1

2}, Antje Willuweit³

Affiliations

¹ Institute of Neuroscience and Medicine, Forschungszentrum Jülich, 52425, Jülich, Germany. k.j.langen@fz-juelich.de.
² Department of Nuclear Medicine, RWTH Aachen University Clinic, 52425, Jülich, Germany. k.j.langen@fz-juelich.de.
³ Institute of Neuroscience and Medicine, Forschungszentrum Jülich, 52425, Jülich, Germany.

Editorial

Karl-Josef Langen et al. Eur J Nucl Med Mol Imaging. 2017 Dec.

. 2017 Dec;44(13):2227-2229.

doi: 10.1007/s00259-017-3838-6. Epub 2017 Oct 12.

Karl-Josef Langen^{1

2}, Antje Willuweit³

¹ Institute of Neuroscience and Medicine, Forschungszentrum Jülich, 52425, Jülich, Germany. k.j.langen@fz-juelich.de.
² Department of Nuclear Medicine, RWTH Aachen University Clinic, 52425, Jülich, Germany. k.j.langen@fz-juelich.de.
³ Institute of Neuroscience and Medicine, Forschungszentrum Jülich, 52425, Jülich, Germany.

No abstract available

Comment on

TSPO PET for glioma imaging using the novel ligand ¹⁸F-GE-180: first results in patients with glioblastoma.
Albert NL, Unterrainer M, Fleischmann DF, Lindner S, Vettermann F, Brunegraf A, Vomacka L, Brendel M, Wenter V, Wetzel C, Rupprecht R, Tonn JC, Belka C, Bartenstein P, Niyazi M. Albert NL, et al. Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2230-2238. doi: 10.1007/s00259-017-3799-9. Epub 2017 Aug 19. Eur J Nucl Med Mol Imaging. 2017. PMID: 28821920